Newsletter Edition
KRAS G12C Did Not Fail. It Was Never a Stable Control Point.
A pre-trial reading of the early sotorasib NSCLC thesis, and the difference between proving a target can be hit and proving that it still governs the disease once heterogeneity returns.
The signal did not weaken. Control was redistributed.
The Core Distinction
KRAS G12C looked decisive because the early biology was real. The error came later. The field treated druggability as if it had already solved control. It had not. A tractable target is not automatically a stable control point, and that is where the thesis became more confident than the disease was simple.
Where the Thesis Held
The early thesis held while KRAS G12C remained the dominant organizing dependency and while the surrounding tumor state stayed quiet enough for the target-led story to remain clean. Inside that window, the mechanism looked exactly as strong as the field wanted it to look. That is why the story became persuasive so quickly.
Where the Thesis Broke
The thesis broke when co-mutation structure, adaptive MAPK rebound, and subgroup biology began deciding outcome more than KRAS G12C alone. That is the fracture line. Not where the target stopped mattering, but where the target stopped governing. The molecule remained real. The disease stopped obeying the simplified story.
What looked like a stronger drug story was, in practice, a narrower control story than the field wanted to admit.
Why This Still Matters
Many oncology programs now sit in exactly this middle state: mechanistically credible, clinically active, and still not boundary-resolved. That is the dangerous stage. The cost of misreading it is rarely immediate collapse. It is premature confidence, and premature confidence is what pushes a real signal into an overextended claim.
What this changes for a live program
The value of the read is not only diagnostic. It changes the next decision. If the confidence claim depends on a boundary that still looks unstable, escalation should pause, narrow, or be re-tested before the claim expands further.
Public evidence can show where the instability sits. High-confidence program-specific resolution still requires internal data, but the decision logic already becomes clearer: do not spend broad confidence where only local support exists.
References
Representative pre-trial references
- KRASG12C Inhibition with Sotorasib in Advanced Solid TumorsPrimary early clinical evidence for the pre-trial KRAS G12C thesis.
- The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunityFoundational preclinical support for target tractability.
- Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C InhibitionPre-trial evidence for feedback resistance and control redistribution.
- Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinomaContext-defining evidence for subgroup structure in KRAS-mutant NSCLC.